The Trade-off Between Speed and Safety in Drug Approvals

JAMA Oncol. 2017 Nov 1;3(11):1465-1466. doi: 10.1001/jamaoncol.2016.3337.

Authors

Anupam B Jena^{1

2

3}, Jie Zhang⁴, Darius N Lakdawalla^{3

5}

Affiliations

¹ Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts.
² Department of Medicine, Massachusetts General Hospital, Boston.
³ National Bureau of Economic Research, Cambridge, Massachusetts.
⁴ Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
⁵ Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles.

PMID: 27684643
DOI: 10.1001/jamaoncol.2016.3337

No abstract available

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Drug Approval / organization & administration*
Drug-Related Side Effects and Adverse Reactions*
Humans
Time Factors
United States
United States Food and Drug Administration

Grants and funding

DP5 OD017897/OD/NIH HHS/United States